Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study) Christian Möller, MD, PhDa, Sten Dreborg, MD, PhDb, Hosne A. Ferdousi, MDc, Susanne Halken, MDd, Arne Høst, MD, PhDe, Lars Jacobsen, MScf, Antti Koivikko, MD, PhDg, Dieter Y. Koller, MDh, Bodo Niggemann, MDi, Lene A. Norberg, MDe, Radvan Urbanek, MD, PhDh, Erkka Valovirta, MD, PhDg, Ulrich Wahn, MD, PhDi Journal of Allergy and Clinical Immunology Volume 109, Issue 2, Pages 251-256 (February 2002) DOI: 10.1067/mai.2002.121317 Copyright © 2002 Mosby, Inc. Terms and Conditions
Fig. 1 Flow chart of the study. Journal of Allergy and Clinical Immunology 2002 109, 251-256DOI: (10.1067/mai.2002.121317) Copyright © 2002 Mosby, Inc. Terms and Conditions
Fig. 2 Development of BHR (methacholine challenge test) within each group measured as natural logarithm of PC20 change from baseline (a) in the season of pollen exposure and (b) during the winter. Journal of Allergy and Clinical Immunology 2002 109, 251-256DOI: (10.1067/mai.2002.121317) Copyright © 2002 Mosby, Inc. Terms and Conditions
Fig. 3 The percentage of children after 3 years of immunotherapy with and without asthma among those without asthma before treatment (N = 151). The absolute numbers of children are shown above the bars . Journal of Allergy and Clinical Immunology 2002 109, 251-256DOI: (10.1067/mai.2002.121317) Copyright © 2002 Mosby, Inc. Terms and Conditions